XLV241206P159000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Merck & Co Unusual Options Activity For December 02
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
December Starts With a Mixed Market | Live Stock
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Microsoft, Others
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data
Ned Davis Research Compares Market's Reaction to Trump's 2016 & 2024 Victories
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Spotlight on AbbVie: Analyzing the Surge in Options Activity
10 Health Care Stocks With Whale Alerts In Today's Session
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR
How Is The Market Feeling About Thermo Fisher Scientific?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Barclays's Options Trading Ideas: Buy XLP, Rent XLF, Sell XLB
Behind the Scenes of Eli Lilly's Latest Options Trends
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum